Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is approved with AVD for stage III-IV HL, but carries i...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramson, Jeremy S., Bengston, Elizabeth, Redd, Robert, Barnes, Jeffrey A., Takvorian, Tak, Sokol, Lubomir, Lansigan, Frederick, Armand, Philippe, Shah, Bijal, Jacobsen, Eric, Martignetti, Rosalba, Turba, Elyce, Metzler, Sara, Patterson, Victoria, LaCasce, Ann S., Bello, Celeste M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111342/
https://www.ncbi.nlm.nih.gov/pubmed/36053786
http://dx.doi.org/10.1182/bloodadvances.2022008420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111342/
https://www.ncbi.nlm.nih.gov/pubmed/36053786
http://dx.doi.org/10.1182/bloodadvances.2022008420

Ejemplares similares